Evaluación del haz espinotalámico mediante tractografía por resonancia magnética: nuevos aportes en la fisiopatología del dolor en pacientes con síndrome X / Spinothalamic Assessment by Magnetic Resonance Tractography: new Contributions in the Pathophysiology of Pain in Patients with Syndrome X

Introducción El síndrome X se asocia con signos y síntomas de isquemia, sin obstrucción significativa de las arterias coronarias. En los pacientes con este síndrome existe un aumento en la percepción de los estímulos cardíacos, aunque la causa de este trastorno se desconoce. Objetivo Explorar los tractos nerviosos sensitivos involucrados en la percepción anormal del dolor en mujeres que sufren de síndrome X. Material y métodos Estudio prospectivo que incluyó 24 mujeres: 12 con síndrome X, 6 con enfermedad coronaria documentada y 6 controles sanas. Se realizó el mapeo del tracto espinotalámico lateral mediante tractografía por difusión. Se analizaron las características anatómicas (líneas, vóxels, longitud) y físicas (anisotropía fraccional, coeficiente de difusión aparente, difusividad) de cada tracto. Resultados El haz espinotalámico lateral se pudo aislar en todas las pacientes evaluadas. No hubo diferencias en las características físicas de los tractos, pero existió una diferencia significativa en el número de vóxels de los tres grupos a expensas del grupo síndrome X (101,2 ± 46,9 vs. 83,2 ± 24 vs. 66 ± 16; p = 0,030), con una tendencia a presentar un número mayor de líneas en cada tracto. Conclusiones Se hallaron diferencias en las características anatómicas de los tractos de las pacientes con síndrome X respecto de los controles sanos y de las pacientes con enfermedad coronaria, con indemnidad en las características físicas de las fibras. Es probable que este estudio experimental sea el primero en demostrar que es posible evaluar in vivo los tractos neurológicos involucrados en la transmisión del dolor en este grupo de pacientes, lo cual abre un nuevo campo de investigación.(AU)

Background Syndrome X is associated with signs and symptoms of ischemia without significant coronary artery obstruction. There is an increased perception of cardiac stimuli in these patients, although the cause of this disorder is unknown. Objective The aim of this study was to analyze sensory nerve tracts involved in abnormal perception of pain in women with syndrome X. Methods This prospective study included 24 women: 12 with syndrome X; 6 with documented coronary heart disease, and 6 healthy controls. Lateral spinothalamic tract mapping by diffusion trac-tography was performed. The anatomic features (lines, voxels, and length) and physical features (fractional anisotropy, apparent diffusion coefficient, diffusivity) of each tract were analyzed. Results The lateral spinothalamic tract was isolated in all patients. No differences were found in the physical characteristics of the tracts, but there was a significant difference in the number of voxels of the syndrome X group when compared to the other two groups (101.2±46.9 vs. 83.2±24 vs. 66±16; p=0.030), with a tendency towards larger number of lines in each tract. Conclusions There were differences in the anatomic characteristics of tracts in syndrome X patients with respect to healthy controls and coronary artery disease patients, with indemnity in the physical characteristics of the fibers. This is probably the first experimental study to show that it is possible to evaluate "in vivo" neurological tracts involved in pain transmission in syndrome X patients, opening a new field of research.(AU)

Evaluación del haz espinotalámico mediante tractografía por resonancia magnética: nuevos aportes en la fisiopatología del dolor en pacientes con síndrome X / Spinothalamic Assessment by Magnetic Resonance Tractography: new Contributions in the Pathophysiology of Pain in Patients with Syndrome X

Introducción El síndrome X se asocia con signos y síntomas de isquemia, sin obstrucción significativa de las arterias coronarias. En los pacientes con este síndrome existe un aumento en la percepción de los estímulos cardíacos, aunque la causa de este trastorno se desconoce. Objetivo Explorar los tractos nerviosos sensitivos involucrados en la percepción anormal del dolor en mujeres que sufren de síndrome X. Material y métodos Estudio prospectivo que incluyó 24 mujeres: 12 con síndrome X, 6 con enfermedad coronaria documentada y 6 controles sanas. Se realizó el mapeo del tracto espinotalámico lateral mediante tractografía por difusión. Se analizaron las características anatómicas (líneas, vóxels, longitud) y físicas (anisotropía fraccional, coeficiente de difusión aparente, difusividad) de cada tracto. Resultados El haz espinotalámico lateral se pudo aislar en todas las pacientes evaluadas. No hubo diferencias en las características físicas de los tractos, pero existió una diferencia significativa en el número de vóxels de los tres grupos a expensas del grupo síndrome X (101,2 ± 46,9 vs. 83,2 ± 24 vs. 66 ± 16; p = 0,030), con una tendencia a presentar un número mayor de líneas en cada tracto. Conclusiones Se hallaron diferencias en las características anatómicas de los tractos de las pacientes con síndrome X respecto de los controles sanos y de las pacientes con enfermedad coronaria, con indemnidad en las características físicas de las fibras. Es probable que este estudio experimental sea el primero en demostrar que es posible evaluar in vivo los tractos neurológicos involucrados en la transmisión del dolor en este grupo de pacientes, lo cual abre un nuevo campo de investigación.

Background Syndrome X is associated with signs and symptoms of ischemia without significant coronary artery obstruction. There is an increased perception of cardiac stimuli in these patients, although the cause of this disorder is unknown. Objective The aim of this study was to analyze sensory nerve tracts involved in abnormal perception of pain in women with syndrome X. Methods This prospective study included 24 women: 12 with syndrome X; 6 with documented coronary heart disease, and 6 healthy controls. Lateral spinothalamic tract mapping by diffusion trac-tography was performed. The anatomic features (lines, voxels, and length) and physical features (fractional anisotropy, apparent diffusion coefficient, diffusivity) of each tract were analyzed. Results The lateral spinothalamic tract was isolated in all patients. No differences were found in the physical characteristics of the tracts, but there was a significant difference in the number of voxels of the syndrome X group when compared to the other two groups (101.2±46.9 vs. 83.2±24 vs. 66±16; p=0.030), with a tendency towards larger number of lines in each tract. Conclusions There were differences in the anatomic characteristics of tracts in syndrome X patients with respect to healthy controls and coronary artery disease patients, with indemnity in the physical characteristics of the fibers. This is probably the first experimental study to show that it is possible to evaluate "in vivo" neurological tracts involved in pain transmission in syndrome X patients, opening a new field of research.

Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [GRACE]).

The risk of stroke in patients hospitalized with an acute coronary syndrome (ACS) ranges from <1% to ≥ 2.5%. The aim of this study was to develop a simple predictive tool for bedside risk estimation of in-hospital ischemic stroke in patients with ACS to help guide clinicians in the acute management of these high-risk patients. Data were obtained from 63,118 patients enrolled from April 1999 to December 2007 in the Global Registry of Acute Coronary Events (GRACE), a multinational registry involving 126 hospitals in 14 countries. A regression model was developed to predict the occurrence of in-hospital ischemic stroke in patients hospitalized with an ACS. The main study outcome was the development of ischemic stroke during the index hospitalization for an ACS. Eight risk factors for stroke were identified: older age, atrial fibrillation on index electrocardiogram, positive initial cardiac biomarkers, presenting systolic blood pressure ≥ 160 mm Hg, ST-segment change on index electrocardiogram, no history of smoking, higher Killip class, and lower body weight (c-statistic 0.7). The addition of coronary artery bypass graft surgery and percutaneous coronary intervention into the model increased the prediction of stroke risk. In conclusion, the GRACE stroke risk score is a simple tool for predicting in-hospital ischemic stroke risk in patients admitted for the entire spectrum of ACS, which is widely applicable to patients in various hospital settings and will assist in the management of high-risk patients with ACS.

Diagnóstico y tratamiento paliativo endovascular de un angiosarcoma de arteria pulmonar / Endovascular diagnosis and palliative treatment of a pulmonary artery angiosarcoma

No disponible

Estimation of coronary length-volume allometric relations of human arteries in vivo using CT.

Assessing the individual geometry of the coronary arteries in a patient can help to explain diffuse artery disease. Some allometric functions, relating arterial length and volume, were verified in porcine arteries and human autopsies but not in vivo. In this work we use skeletonization methods on MSCT images to render the whole coronary tree in healthy and cardiovascular patients. Twenty patients with and without coronary artery disease were recruited. The coronary was segmented with minimum user intervention. Vessels were separated and measured. A 3D coronary map was individually calculated. The allometric length-volume function L=k(v)V(ß) was evaluated in each patient and plotted in a Log-Log scale. The coefficient k(v) ranged 1.00 ± 0.35. Slopes ranged ß = 0.69-0.88 and seemed to overlap in the scatter Log plot. The analysis of covariance verified this perception and concluded that lines were parallel. In other words, the allometric function stood for all patients. Values were not different from other studies in humans and pigs. The combination of multislice CT with morphological extraction algorithms was effective to extract allometric functions from coronary arteries in patients and can be easily applied in the clinic.

Clínica y seguimiento de la pericarditis constrictiva crónica / Clinical finding and follow up of chronic constrictive pericarditis

El objetivo de este estudio fue describir la etiología, presentación clínica, métodos diagnósticos, tratamiento, evolución y pronóstico alejado de 35 pacientes con pericarditis constrictiva crónica que fueron evaluados prospectivamente de acuerdo a un protocolo de enfermedad pericárdica que se aplica en nuestra Institución. En 24 (68%) la pericarditis constrictiva fue idiopática y 11 (32%) presentaron etiología definida, realizándose pericardiectomía en 34 (97%). Hubo 4 (12%) muertes intrahospitalarias, todas con etiología definida. La mediana de seguimiento fue de 5.6 años (percentilos 25-75: 2.4-7.4 años). La supervivencia de acuerdo al método de Kaplan-Meier fue de 97% al año (IC 95% 80 - 99%), 83% a los 5 años (IC 95% 65 - 93%), 78% a los 7 años (IC 95% 60 - 90%), y 69% a los 10 años (IC 95% - 50% - 84%). En conclusión, la pericarditis constrictiva crónica es una enfermedad generalmente idiopática, de diagnóstico tardío, cuyo tratamiento es la pericardiectomía. Los pacientes con etiología específica presentaron mayor mortalidad intrahospitalaria. En el seguimiento a 10 años 2/3 de los pacientes están vivos y con mejoría de los síntomas.

The aim of this study was to describe the etiology, clinical findings, diagnostic methods, treatment, outcome and long-term prognosis of 35 patients with chronic constrictive pericarditis (CCP) that were prospectively analyzed according to a pericardial disease protocol performed in our Institution. Etiology of CCP was idiopathic in 24 patients (68%), and specific in 11 (32%). The majority (34 patients, 97%) underwent pericardiectomy. Perioperative mortality was 12% (4/33) no deaths were registered among patients with idiopathic CCP. Median follow-up was 5.6 years (percentile 25-75: 2.4-7.4 years). The cumulative actuarial survival probability was 97% at 1 year (confidence interval [CI] 80% to 99%); 83% at 5 years, (95% CI 65% to 93%); 78% at 7 years, (95% CI 60% to 90%), and 69% at 10 years (95% CI 50% to 84%). In conclusion, nowadays CCP is generally an idiopathic disease with late diagnosis. The clinical course of the disease produces severe symptoms of congestive heart failure. In a 10 years follow-up 2/3 of patients are alive and improved their quality of life. Idiopathic form of pericarditis did not show mortality during early postoperative period.

Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry.

BACKGROUND: A limited number of studies have examined the age and sex differences, and potentially changing trends, in cardiac medication and procedure use in patients hospitalized with an acute coronary syndrome (ACS). METHODS: Using data from a large multinational study, we examined the age and sex differences, and changing trends (1999-2007) therein, in the hospital use of evidence-based therapies in patients hospitalized with an ACS using data from the Global Registry of Acute Coronary Events (n=50 096). RESULTS: After adjustment for several variables, in comparison with men below 65 years, patients in other age-sex strata had a significantly lower odds of receiving aspirin [odds ratios (ORs) for men 65-74, 75-84, and >or=85 years, women <65, 65-74, 75-84, and >or=85 years were 0.86, 0.84, 0.72, 0.80, 0.86, 0.68 and 0.46, respectively], angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ORs, 1.08, 1.01, 0,71, 0.83, 0.90, 0.89, and 0.63), beta blockers (ORs, 0.66, 0.52, 0.53, 0.67, 0.54, 0.53, and 0.52), statins (ORs, 0.72, 0.49, 0.29, 0.82, 0.68, 0.44, and 0.22), and undergoing coronary artery bypass graft surgery or a percutaneous coronary intervention (ORs, 0.79, 0.53, 0.21, 0.64, 0.57, 0.38, and 0.13) during their acute hospitalization. Age and sex differences in the receipt of these therapies remained relatively unchanged during the period under study. CONCLUSION: Although there were increasing trends in the use of evidence-based medications and cardiac procedures over time, important gaps in the utilization of effective cardiac treatment modalities persist in elderly patients and younger women.

Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events.

AIMS: To determine the incidence and factors associated with heart rupture (HR) in acute coronary syndrome (ACS) patients. METHODS AND RESULTS: Among 60 198 patients, 273 (0.45%) had HR (free wall rupture, n = 118; ventricular septal rupture, n = 155). Incidence was 0.9% for ST-segment elevation myocardial infarction (STEMI), 0.17% for non-STEMI, and 0.25% for unstable angina. Hospital mortality was 58 vs. 4.5% in patients without HR (P < 0.001). The incidence was lower in STEMI patients with primary percutaneous coronary intervention (PCI) than in those without (0.7 vs. 1.1%; P = 0.01), but primary PCI was not independently related to HR in adjusted analysis (P = 0.20). Independent variables associated with HR included: ST-segment elevation (STE)/left bundle branch block; ST-segment deviation; female sex; previous stroke; positive initial cardiac biomarkers; older age; higher heart rate; systolic blood pressure/30 mmHg decrease. Conversely, previous MI and the use of low-molecular-weight heparin and beta-blockers during first 24 h were identified as protective factors for HR. CONCLUSION: The incidence of HR is low in patients with ACS, although its incidence is probably underestimated. Heart rupture occurs more frequently in ACS with STE and is associated with high hospital mortality. A number of variables are independently related to HR.

Recurrent ischemia across the spectrum of acute coronary syndromes: prevalence and prognostic significance of (re-)infarction and ST-segment changes in a large contemporary registry.

BACKGROUND: There are limited recent data on the prevalence and potentially different adverse impact of the various types of recurrent ischemia (RI) in unselected patients with acute coronary syndromes(ACS). We examined the clinical features and treatment associated with, and the differential prognostic impact of, the various types of RI in unselected patients across the broad spectrum of ACS in the contemporary era. METHODS: The Global Registry of Acute Coronary Events (GRACE) was a prospective, multinational registry of patients hospitalized for ACS. Data were collected on standardized case report forms. RESULTS: Of the 29,400 ACS patients enrolled in May 2000-March 2007, 21% developed RI; 2.4%, 4.9%, and 16% had myocardial (re-)infarction [(re-)MI], RI with ST-segment changes, and RI without ST-segment changes (not mutually exclusive), respectively. Rates of in-hospital mortality and complications, and 6-month mortality were significantly higher among patients with RI compared to those without; the rates were highest for patients who developed (re-)MI, followed by those with RI and ST-segment changes. After adjusting for other validated prognosticators in the GRACE risk score, all three types of RI retained an independent association with both higher in-hospital and post-discharge 6-month mortality. Early revascularization was associated with lower in-hospital mortality only in the group with (re-)MI (P for interaction=0.003). CONCLUSIONS: Despite the current use of intensive medical therapies, RI remains a common and serious consequence across the spectrum of ACS. Different types of RI confer a variable adverse prognostic impact. Re-MI is associated with the worst outcome, which appears to be mitigated by early revascularization. Our findings underscore the persistent need to improve the treatment of ACS.

Coronary arteries simplified with 3D cylinders to assess true bifurcation angles in atherosclerotic patients.

The geometry of coronary arteries affects regional atherogenic processes. Accurate images can be assessed using multislice computer tomography (MSCT) to estimate bifurcations angles. We propose a three-dimensional (3D) method to measure true bifurcation angles of coronary arteries and to determine possible correlations between plaque presence and angulations. The left main (LM) coronary artery, left anterior descendent (LAD) and left circumflex artery (LCX) were imaged in 40 atherosclerotic and 35 healthy patients, using 64-rows MSCT. This Y-junction was simplified fitting a 3D cylinder to each vessel to estimate true bifurcation angles and diameters. The method was tested in phantoms and interobserver variability was assessed. Geometrical results were compared between groups using an unpaired t-test. The cylinders fitted reasonably well with mean distances to measured points below 0.4 mm. LAD-LCX bifurcation angles were wider in the atherosclerotic group (p < 0.01). LAD (p < 0.01) and LCX (p < 0.05) diameters were also larger. In phantoms mean absolute difference between true and estimated angles (N = 27) was 0.44 +/- 0.54 degrees . Interobserver mean difference (N = 135) was 1.8 +/- 5.8 degrees . Simplifying coronary bifurcation with cylinders results in a reliable technique to assess coronary artery geometry in 3D, avoiding planar projections and decreasing interobserver variability. Geometrical risk factors should be incorporated to properly predict atherosclerosis processes.

In-hospital outcomes associated with fibrinolytic and thienopyridine use in patients with ST-segment elevation acute myocardial infarction. The global registry of acute coronary events.

INTRODUCTION AND OBJECTIVES: To investigate how thienopyridine treatment, with or without associated fibrinolysis, affects the rates of major bleeding and inhospital death in patients with ST-elevation myocardial infarction (STEMI). METHODS: The rates of major bleeding and in-hospital death were studied in 14,259 consecutive patients with STEMI. During hospitalization, 5340 (38%) received thienopyridines, 3007 (21%) received fibrinolytic drugs, and 2044 (14%) received both. RESULTS: Major bleeding occurred more frequently in patients who received thienopyridines with or without fibrinolytics, in 4.6% and 4.1%, respectively, compared with 2.3% in those who received fibrinolytics alone and 2.8% in those who received neither (P< .001). Multivariate analysis, which included adjustments for risk factors for bleeding, percutaneous coronary intervention and cardiac catheterization, showed that thienopyridine treatment was an independent risk factor for bleeding (odds ratio=1.68; 95% confidence interval, 1.23-2.31). In-hospital mortality was lower in patients who received a thienopyridine, and such treatment was an independent predictor of lower mortality (odds ratio=0.50; 95% confidence interval, 0.39-0.60). CONCLUSIONS: Thienopyridine treatment was associated with an increased risk of major bleeding but also with a better in-hospital prognosis. These findings in unselected patients with STEMI, who are representative of those seen in daily clinical practice, complement, but do not replace, the data obtained in randomized clinical trails of selected patients.

Evolución hospitalaria asociada al empleo de fibrinolíticos y tienopiridinas en pacientes con infarto agudo de miocardio y elevación del segmento ST. The Global Registry of Acute Coronary Events / In-hospital outcomes associated with fibrinolytic and thienopyridine use in patients with ST-segment elevation acute myocardial infarction. The Global Registry of Acute Coronary Events

Introducción y objetivos. Investigar la incidencia de hemorragias graves y la mortalidad hospitalaria en pacientes con infarto de miocardio y elevación del segmento ST (IAMCEST) en relación con la administración de tienopiridinas con o sin tratamiento trombolítico asociado. Métodos. Se estudió la incidencia de hemorragias graves y mortalidad hospitalaria en 14.259 pacientes consecutivos con IAMCEST. En total, 5.340 (38%) pacientes recibieron tratamiento con tienopiridinas, 3.007 (21%) recibieron fármacos trombolíticos y 2.044 (14%), ambos tipos de fármacos durante el periodo de hospitalización. Resultados. Las hemorragias graves fueron más frecuentes en los pacientes que recibieron tienopiridinas con o sin fármacos trombolíticos asociados (el 4,6 y el 4,1%, respectivamente) que en los pacientes que sólo recibieron fibrinolíticos (2,3%) o ninguno de los dos tipos de fármacos (2,8%) (p < 0,001). En el análisis multivariable, ajustado para los factores de riesgo hemorrágico y cateterismo cardiaco o intervención coronaria percutánea, el tratamiento con tienopiridinas se identificó como un factor independiente de hemorragia (odds ratio [OR] = 1,68; intervalo de confianza [IC] del 95%, 1,23-2,31). La mortalidad intrahospitalaria fue menor en los pacientes que recibieron tienopiridinas, lo que se identificó como factor independiente relacionado con menor mortalidad (OR = 0,50; IC del 95%, 0,39-0,60). Conclusiones. El tratamiento con tienopiridinas se asoció con un aumento del riesgo de hemorragias, pero con mejor pronóstico intrahospitalario. Estos resultados, en pacientes no seleccionados con diagnóstico de IAMCEST y representativos de la práctica clínica diaria complementan, pero no reemplazan, la información derivada de ensayos clínicos en enfermos seleccionados y con distribución aleatoria del tratamiento (AU)

Introduction and objectives. To investigate how thienopyridine treatment, with or without associated fibrinolysis, affects the rates of major bleeding and inhospital death in patients with ST-elevation myocardial infarction (STEMI). Methods. The rates of major bleeding and in-hospital death were studied in 14 259 consecutive patients with STEMI. During hospitalization, 5340 (38%) received thienopyridines, 3007 (21%) received fibrinolytic drugs, and 2044 (14%) received both. Results. Major bleeding occurred more frequently in patients who received thienopyridines with or without fibrinolytics, in 4.6% and 4.1%, respectively, compared with 2.3% in those who received fibrinolytics alone and 2.8% in those who received neither (P < .001). Multivariate analysis, which included adjustments for risk factors for bleeding, percutaneous coronary intervention, and cardiac catheterization, showed that thienopyridine treatment was an independent risk factor for bleeding (odds ratio =1.68; 95% confidence interval, 1.23-2.31). In-hospital mortality was lower in patients who received a thienopyridine, and such treatment was an independent predictor of lower mortality (odds ratio =0.50; 95% confidence interval, 0.39-0.60). Conclusions. Thienopyridine treatment was associated with an increased risk of major bleeding but also with a better in-hospital prognosis. These findings in unselected patients with STEMI, who are representative of those seen in daily clinical practice, complement, but do not replace, the data obtained in randomized clinical trails of selected patients. risk factor for bleeding (odds ratio=1.68; 95% confidence interval, 1.23-2.31). In-hospital mortality was lower in patients who received a thienopyridine, and such treatment was an independent predictor of lower mortality (odds ratio=0.50; 95% confidence interval, 0.39-0.60). Conclusions. Thienopyridine treatment was associated with an increased risk of major bleeding but also with a better in-hospital prognosis. These findings in unselected patients with STEMI, who are representative of those seen in daily clinical practice, complement, but do not replace, the data obtained in randomized clinical trails of selected patients (AU)

Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]).

The incidence of thrombocytopenia after hospital admission, patient and treatment characteristics, and outcomes in patients enrolled in the prospective multinational GRACE were examined. Heparin (unfractionated or low molecular weight) and glycoprotein IIb/IIIa-inhibition can be associated with immune-mediated thrombocytopenia of clinical importance. The prevalence of thrombocytopenia in patients with acute coronary syndromes (ACSs) in general and specifically related to these therapies and associated outcomes have been studied little outside of clinical trials. Patients with an ACS were stratified into 4 groups of those with heparin-induced thrombocytopenia (HIT), those with glycoprotein IIb/IIIa-associated thrombocytopenia (GAT), those with other thrombocytopenia (not diagnosed as HIT or associated with glycoprotein inhibitors), and those with no thrombocytopenia. From June 2000 to September 2007, a total of 52,647 patients with an ACS and information for platelet count were enrolled in GRACE. Of these, 152 (0.3%) were reported to develop HIT, 324 (0.6%) developed GAT, and 368 (0.7%) developed other thrombocytopenia. Patients with HIT, GAT, or other thrombocytopenia were significantly more likely to die in the hospital versus those without these diseases (adjusted odds ratio [OR] 1.94, 95% confidence interval [CI] 1.07 to 3.53; adjusted OR 3.45, 95% CI 2.35 to 5.05; and adjusted OR 2.83, 95% CI 1.97 to 4.06, respectively). They were also more likely to experience major bleeding, (re)infarction, or stroke. In conclusion, in this large multinational registry, 1.6% of patients with ACS were reported to develop thrombocytopenia, with only 0.3% being HIT. Regardless of whether patients had clinically recognized HIT, GAT, or other thrombocytopenia, all 3 groups had significantly higher rates of major bleeding, recurrent infarction, stroke, and death.

Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspective.

BACKGROUND: Current practice guidelines recommend the routine use of several effective cardiac medications in hospital survivors of acute myocardial infarction (AMI). METHODS: We explored a recent 5-year (2000-2005) trend in hospital use of aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, lipid-lowering agents, and combinations thereof, in 26 413 adult men and women without contraindications to any of these therapies discharged after AMI from hospitals located in 14 countries that were included in the Global Registry of Acute Coronary Events. RESULTS: Relatively steady increases in the use of ACE inhibitors, beta-blockers, and statin therapy were observed over time, with particularly marked increases in the use of lipid-lowering therapy (from 45% in 2000 to 85% in 2005). Aspirin use remained high (by approximately 95% of patients after AMI) during all periods examined. The percentage of hospital survivors treated with all 4 cardiac medications increased from 23% in 2000 to 58% during 2005. Advancing age (>/= 65 years), female sex, medical history of heart failure or stroke, and development of atrial fibrillation during hospitalization were associated with underuse of combination medical therapy. Relatively similar factors were associated with the underuse of combination medical therapy in patients with ST-segment elevation AMI and non-ST-segment elevation AMI. CONCLUSIONS: Our results suggest encouraging increases over time in the use of combination medical therapy in patients hospitalized with AMI without contraindications to these medications. Educational efforts designed to increase the use of these therapies, as well as efforts to simplify medication regimens and enhance rates of adherence, remain warranted.

Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.

AIMS: We compared outcomes of ST-elevation myocardial infarction (STEMI) patients randomized to a strategy of either enoxaparin or unfractionated heparin (UFH) to support fibrinolysis. METHODS AND RESULTS: In the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction Study 25 (ExTRACT-TIMI 25) trial, 20,479 patients undergoing fibrinolysis for STEMI with a fibrin-specific agent (N = 16,283) or streptokinase (SK) (N = 4139) were randomized to enoxaparin throughout their hospitalization or UFH for at least 48 h. The primary end point of death or nonfatal recurrent MI through 30 days occurred in 12.0% of patients in the UFH and 9.8% in the enoxaparin groups when treated with fibrin-specific lytics [odds ratio(adjusted) (OR(adj)) 0.78; 95% CI 0.70-0.87; P < 0.001] and 11.8 vs. 10.2%, respectively, when treated with SK (OR(adj) 0.83; 95% CI 0.66-1.04; P = 0.10; P(interaction) = 0.58). Major bleeding rates including intracranial hemorrhage within the fibrin-specific cohort were 1.2 and 2.0% in the UFH and enoxaparin groups, respectively (P < 0.001) and 2.0% in UFH and 2.4% in enoxaparin patients in the SK cohort (P = 0.16). Interaction tests between antithrombin- and lytic-type were non-significant (P = 0.20). Death, nonfatal MI, or major bleeding was significantly reduced with enoxaparin in the fibrin-specific cohort (OR(adj) 0.82; 95% CI 0.74-0.91; P < 0.001) and favoured enoxaparin in the SK cohort (OR(adj) 0.89; 95% CI 0.72-1.10; P = 0.29; P(interaction) = 0.53). CONCLUSION: The benefits of an enoxaparin strategy over UFH were observed in both SK and fibrin-specific-treated STEMI patients. Therefore, an enoxaparin strategy is preferred over UFH to support fibrinolysis for STEMI regardless of lytic agent.

Advances in coronary heart disease surgery in Latin America.

BACKGROUND: The beginnings of coronary artery bypass graft in Latin America could be set in the year 1971. Since then, improvements in technique and greater experience have resulted in a rapid increase in the rate of interventions performed in the region. METHODS AND RESULTS: Searches through PubMed and Literatura Latinoamericana y del Caribe en Ciencias de la Salud, as well as personal communications from specialists from Latin America, have been the source of information. Articles were selected by their content related to the theme, and the authors' nationality and information is mainly from Latin America. Demographic information of the population of Latin America denotes higher age averages, and this implies an increase in the severity of comorbidities in patients who undergo surgery. Longer life expectancy and improvements in medical therapy have implied that patients survive a first intervention beyond the expected time a bypass persists patent. Wall vessel properties of arterial conduits, plus a better anastomotic technique, seem to be the current solution to worsening in the coronary health of patients who undergo revascularization surgery in Latin America. CONCLUSIONS: Despite scarce economic investment in medical sciences, many academic groups contribute to the exploration of therapeutic pharmacological combinations and inclusively apply genetic strategies.

Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial).

Management and outcomes of patients with acute coronary syndromes (ACSs) may vary according to patient race and ethnicity. To assess racial differences in presentation and outcome in high-risk North American patients with non-ST-segment elevation (NSTE) ACS, we analyzed baseline racial/ethnic differences and all-cause death or nonfatal myocardial infarction (MI) in 6,077 white, 586 African-American, and 344 Hispanic patients through 30-day, 6-month, and 1-year follow-up. Frequencies of hypertension were 66% for whites, 83% for African-Americans, and 78% for Hispanics (overall p <0.001). Use of angiography was similar across groups. Use of percutaneous coronary intervention (46% for whites, 41% for African-Americans, and 45% for Hispanics, overall p = 0.046) and coronary artery bypass grafting (20% for whites, 16% for African-Americans, and 22% for Hispanics, overall p = 0.044) differed. African-American patients had significantly fewer diseased vessels compared with white patients (p = 0.0001). Thirty-day death or MI was 14% for whites, 10% for African-Americans, and 14% for Hispanics (overall p = 0.034). After adjustment for baseline variables, African-American patients had lower 30-day death or MI compared with white patients (odds ratio 0.73, 95% confidence interval 0.55 to 0.98). There were no differences in 6-month death or MI across racial/ethnic groups. In conclusion, baseline clinical characteristics differed across North American racial/ethnic groups in the SYNERGY trial. African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients.